SAN FRANCISCO, November 03, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy ...
Vir Biotechnology (VIR) is advancing its ECLIPSE phase 3 program for tobevibart + elebsiran in Hepatitis Delta Virus, with topline data from all 3 studies expected Q1 2027. Company's dual-masked ...
November 20, 2025 • He made a splash on The Voice, but Gaspard has been a longtime part of Louisiana's Cajun and swamp pop music scene.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback